Saniona Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Saniona de 45.1% y 43.6%, respectivamente.

Información clave

45.1%

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	39.6%
Tasa de crecimiento de los ingresos	43.6%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	01 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?

Jan 06

Is Saniona (STO:SANION) Using Too Much Debt?

Dec 02

Previsiones de crecimiento de beneficios e ingresos

OM:SANION - Estimaciones futuras de los analistas y datos financieros pasados (SEK Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	56	-43	-19	-19	1
12/31/2024	62	-37	-35	-35	1
12/31/2023	17	-96	-86	-86	N/A
9/30/2023	15	-108	-84	-84	N/A
6/30/2023	12	-66	-101	-100	N/A
3/31/2023	11	-134	-212	-211	N/A
12/31/2022	15	-245	-283	-282	N/A
9/30/2022	15	-334	-331	-331	N/A
6/30/2022	15	-445	-383	-382	N/A
3/31/2022	14	-461	-325	-324	N/A
12/31/2021	10	-411	-347	-345	N/A
9/30/2021	9	-326	-326	-323	N/A
6/30/2021	9	-280	-296	-291	N/A
3/31/2021	9	-200	-244	-239	N/A
12/31/2020	8	-73	-179	-174	N/A
9/30/2020	11	-25	-153	-145	N/A
6/30/2020	9	-5	-124	-119	N/A
3/31/2020	8	-1	-132	-127	N/A
12/31/2019	7	-69	-102	-99	N/A
9/30/2019	5	-96	-90	-89	N/A
6/30/2019	49	-53	-42	-42	N/A
3/31/2019	52	-52	-31	-30	N/A
12/31/2018	55	-41	-24	-23	N/A
9/30/2018	57	-32	-33	-33	N/A
6/30/2018	17	-61	-72	-71	N/A
3/31/2018	17	-56	-62	-62	N/A
12/31/2017	21	-49	-58	-57	N/A
9/30/2017	21	-47	N/A	-50	N/A
6/30/2017	68	-6	N/A	-3	N/A
3/31/2017	67	-2	N/A	-5	N/A
12/31/2016	75	2	N/A	8	N/A
9/30/2016	71	10	N/A	3	N/A
6/30/2016	23	-25	N/A	-32	N/A
3/31/2016	25	-21	N/A	-25	N/A
12/31/2015	14	-23	N/A	-29	N/A
9/30/2015	16	-23	N/A	-18	N/A
6/30/2015	19	-16	N/A	-15	N/A
3/31/2015	23	-10	N/A	-5	N/A
12/31/2014	22	-6	N/A	-8	N/A
12/31/2013	13	-1	N/A	-4	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que SANION siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que SANION siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que SANION siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (43.6% al año) de SANION crezcan más rápidamente que los del mercado Swedish (1.5% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (43.6% al año) de SANION crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de SANION se prevé que sea elevada dentro de 3 años.

Saniona Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 37% to kr6.00

Recent updates

Saniona AB (publ) to Report Fiscal Year 2023 Results on Apr 30, 2024

Full year 2023 earnings released: kr1.49 loss per share (vs kr3.93 loss in FY 2022)

New major risk - Shareholder dilution

Price target decreased by 37% to kr6.00

Saniona Announces the Selection of Its Proprietary GABAA A5 Negative Allosteric Modulator (NAM) Lead Compound, San2465

Saniona AB (publ) Strengthens Epilepsy Pipeline with Selection of SAN2355 as Clinical Candidate

Third quarter 2023 earnings released: kr0.38 loss per share (vs kr0.28 profit in 3Q 2022)

Saniona AB (publ) to Report Fiscal Year 2024 Results on Feb 27, 2025

Saniona AB (publ), Annual General Meeting, May 29, 2024

Saniona (STO:SANION) Is Making Moderate Use Of Debt

Saniona Promotes Kv7 Epilepsy Compound to Candidate Selection Phase

Second quarter 2023 earnings released: kr0.34 loss per share (vs kr1.42 loss in 2Q 2022)

New minor risk - Shareholder dilution

Is Saniona (STO:SANION) Using Too Much Debt?

First quarter 2023 earnings released: kr0.35 loss per share (vs kr2.14 loss in 1Q 2022)

Full year 2022 earnings released: kr3.93 loss per share (vs kr6.59 loss in FY 2021)

Saniona AB Appoints Nomination Committee for the Annual General Meeting 2023

Third quarter 2022 earnings released: EPS: kr0.28 (vs kr1.50 loss in 3Q 2021)

Saniona AB (publ) to Report Q1, 2023 Results on May 25, 2023

Insufficient new directors

Saniona AB (publ) Announces Anti-Inflammatory and Anti-Fibrotic Candidate SAN903 Is Ready for Clinical Studies

Second quarter 2022 earnings released: kr1.42 loss per share (vs kr1.67 loss in 2Q 2021)

Saniona Progresses Its Kv7 Epilepsy Program into Lead Optimization

Saniona Reports Positive Top Line Results from the SAN711 Phase 1 Clinical Trial

Insufficient new directors

Saniona’S Preclinical Candidate San903 Shows Robust Dampening of Fibrosis in Chronic Kidney Disease Model

Saniona Provides Update on Ongoing Review of Tesofensine in Mexico

Saniona Appoints Anita Milland as Chief Financial Officer, Effective April 30, 2022

Saniona Announces Voluntary Pause of Phase 2B Clinical Trials of Tesomet for Hypothalamic Obesity and Prader-Willi Syndrome

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Saniona AB (publ) to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Saniona Initiates Multiple Ascending Dose Stage of SAN711 Phase 1 Clinical Trial

Saniona Initiates Phase 2b Clinical Trial of Tesomet for Prader-Willi Syndrome

President & CEO recently bought kr100k worth of stock

Independent Chairman of the Board recently bought kr229k worth of stock

Third quarter 2021 earnings released: kr1.50 loss per share (vs kr1.24 loss in 3Q 2020)

Second quarter 2021 earnings released: kr1.67 loss per share (vs kr1.24 loss in 2Q 2020)

Saniona Initiates Phase 1 Clinical Trial of SAN711

Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology

First quarter 2021 earnings released: kr1.34 loss per share (vs kr1.47 profit in 1Q 2020)

Full year 2020 earnings released: kr1.79 loss per share (vs kr2.95 loss in FY 2019)

Is Saniona (STO:SANION) Using Too Much Debt?

Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity

Saniona Receives U.S. FDA Orphan Drug Designation for Tesomet in Prader-Willi Syndrome

New 90-day low: kr18.70

Need To Know: Saniona AB (publ) (STO:SANION) Insiders Have Been Buying Shares

Novartis AG (SWX:NOVN) completed the acquisition of Cadent Therapeutics, Inc. from a group of sellers.

New 90-day low: kr20.10

What Type Of Shareholders Make Up Saniona AB (publ)'s (STO:SANION) Share Registry?

New 90-day low: kr20.70

Saniona Announces Management Appointments

Co-Founder recently bought kr108k worth of stock

Co-Founder recently bought kr115k worth of stock

New 90-day low: kr22.55

Is Saniona (STO:SANION) Using Too Much Debt?

Third quarter 2020 earnings released: kr1.24 loss per share

Saniona AB (publ) to Report Fiscal Year 2021 Results on Feb 24, 2022

Saniona AB (publ) Appoints Nomination Committee Members

Saniona Reports Positive Topline Results from Tesomet Phase 2 Open-Label Extension Study in Hypothalamic Obesity

New 90-day low: kr24.70

Saniona Receives Pre-IND Feedback from FDA on Regulatory Path for Tesomet in Prader-Willi Syndrome (PWS) and Hypothalamic Obesity (HO)

Earnings released

Saniona AB (publ) has completed a Follow-on Equity Offering in the amount of $64.999993 million.

New 90-day high - kr42.50

An unknown buyer acquired 3.96% stake in Scandion Oncology A/S (NGM:SCOL) from Saniona AB (publ) (OM:SANION) for for $2.3 million.

New 90-day high - kr29.30

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento